Biocytogen Pharmaceuticals (Beijing) Co (HKSE:02315) Market Cap : HK$4,541 Mil (As of Apr. 22, 2025)

View and export this data going back to 2022. Start your Free Trial

What is Biocytogen Pharmaceuticals (Beijing) Co Market Cap?

Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Biocytogen Pharmaceuticals (Beijing) Co's share price for the quarter that ended in Dec. 2024 was HK$8.42. Biocytogen Pharmaceuticals (Beijing) Co's Shares Outstanding (EOP) for the quarter that ended in Dec. 2024 was 398 Mil. Therefore, Biocytogen Pharmaceuticals (Beijing) Co's market cap for the quarter that ended in Dec. 2024 was HK$3,349 Mil.

Biocytogen Pharmaceuticals (Beijing) Co's quarterly market cap declined from Dec. 2023 (HK$4,771 Mil) to Jun. 2024 (HK$3,047 Mil) but then increased from Jun. 2024 (HK$3,047 Mil) to Dec. 2024 (HK$3,349 Mil).

Biocytogen Pharmaceuticals (Beijing) Co's annual market cap declined from Dec. 2022 (HK$10,245 Mil) to Dec. 2023 (HK$4,771 Mil) and declined from Dec. 2023 (HK$4,771 Mil) to Dec. 2024 (HK$3,351 Mil).

Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Biocytogen Pharmaceuticals (Beijing) Co's Enterprise Value for Today is HK$4,880 Mil.

Biocytogen Pharmaceuticals (Beijing) Co Market Cap Historical Data

The historical data trend for Biocytogen Pharmaceuticals (Beijing) Co's Market Cap can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biocytogen Pharmaceuticals (Beijing) Co Market Cap Chart

Biocytogen Pharmaceuticals (Beijing) Co Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Dec24

Market Cap

10,244.56

4,771.04

3,351.25

Biocytogen Pharmaceuticals (Beijing) Co Semi-Annual Data
	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
Market Cap	Get a 7-Day Free Trial				10,244.56	8,387.36	4,771.04	3,047.38	3,349.10

Competitive Comparison of Biocytogen Pharmaceuticals (Beijing) Co's Market Cap

For the Biotechnology subindustry, Biocytogen Pharmaceuticals (Beijing) Co's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Biocytogen Pharmaceuticals (Beijing) Co's Market Cap Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Biocytogen Pharmaceuticals (Beijing) Co's Market Cap distribution charts can be found below:

* The bar in red indicates where Biocytogen Pharmaceuticals (Beijing) Co's Market Cap falls into.

Save Embed

;

Save Embed

;

Biocytogen Pharmaceuticals (Beijing) Co Market Cap Calculation

Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.

Biocytogen Pharmaceuticals (Beijing) Co's Market Cap for the fiscal year that ended in Dec. 2024 is calculated as

Market Cap (A: Dec. 2024 )	=	Share Price (A: Dec. 2024 )	*	Shares Outstanding (EOP) (A: Dec. 2024 )
	=	HK$8.42	*	398.011
	=	HK$3,351

Biocytogen Pharmaceuticals (Beijing) Co's Market Cap for the quarter that ended in Dec. 2024 is calculated as

Market Cap (Q: Dec. 2024 )	=	Share Price (Q: Dec. 2024 )	*	Shares Outstanding (EOP) (Q: Dec. 2024 )
	=	HK$8.42	*	397.755
	=	HK$3,349

Biocytogen Pharmaceuticals (Beijing) Co (HKSE:02315) Market Cap Explanation

Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.

Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.

Biocytogen Pharmaceuticals (Beijing) Co Market Cap Related Terms

Thank you for viewing the detailed overview of Biocytogen Pharmaceuticals (Beijing) Co's Market Cap provided by GuruFocus.com. Please click on the following links to see related term pages.

Biocytogen Pharmaceuticals (Beijing) Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Biocytogen Pharmaceuticals (Beijing) Co Ltd (HKSE:02315) » Definitions » Market Cap

Comparable Companies

Traded in Other Exchanges

I54:Germany

Address

12 Baoshen South Street, Daxing Bio-Medicine Industry Park, Daxing District, Beijing, CHN

Website

https://www.biocytogen.com.cn

Biocytogen Pharmaceuticals (Beijing) Co Ltd is a biopharmaceutical and pre-clinical research services company. It has two Core Products, YH003 and YH001. YH003 is a recombinant humanized agonistic anti-Cluster of Differentiation 40 (CD40) Immunoglobulin G2 (IgG2) monoclonal antibody and YH001 is a recombinant humanized anti-CTLA-4, a protein receptor expressed constitutively on T cells that functions as an immune checkpoint and downregulates immune responses, Immunoglobulin G1 (IgG1) monoclonal antibody. YH003 is being developed for pancreatic ductal adenocarcinoma, melanoma, and other advanced solid tumors. YH001 is being developed for hepatocellular carcinoma (HCC), non-small-cell lung carcinoma (NSCLC), and other solid tumors.

Executives

Wei Ke Xiang Gang Jing Mao You Xian Gong Si	2101 Beneficial owner
Bvcf Realization Fund, L.p.	2201 Interest of corporation controlled by you
Zhao Yin Guo Ji Jin Rong You Xian Gong Si	2201 Interest of corporation controlled by you
Zhao Yin Guo Ji Jin Rong Kong Gu You Xian Gong Si	2201 Interest of corporation controlled by you
Prowell Ventures Pte Ltd	2201 Interest of corporation controlled by you
Gic Special Investments Private Limited	2102 Investment manager
Gic Private Limited	2201 Interest of corporation controlled by you
Gic (ventures) Pte. Ltd.	2201 Interest of corporation controlled by you
Yang Zhi	2201 Interest of corporation controlled by you
Innoveda Medtech, Ltd.	2201 Interest of corporation controlled by you
Ni Jian
Bvcf Realization Fund Gp, Ltd.	2201 Interest of corporation controlled by you
Bioveda China Fund Ii Rmb, Limited	2101 Beneficial owner
Cmbi Private Equity Series Spc	2201 Interest of corporation controlled by you
Cmb International Private Investment Limited	2201 Interest of corporation controlled by you

Biocytogen Pharmaceuticals (Beijing) Co Headlines

No Headlines